Pathogenic Study of Adult Immune Enteropathies (ENTEROPAH)

The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Clichy, France, 92110
        • Not yet recruiting
        • Hopital Beaujon
        • Contact:
        • Principal Investigator:
          • Yoram Bouhnik, MD, PhD
        • Sub-Investigator:
          • Xavier Treton, MD, PhD
      • Créteil, France, 94010
        • Not yet recruiting
        • Hopital Henri Mondor
        • Contact:
        • Principal Investigator:
          • Iradj Sobhani, MD, PhD
        • Sub-Investigator:
          • Aurélien Amiot, MD, PhD
      • Le Kremlin Bicêtre, France, 94270
        • Not yet recruiting
        • Hôpital Bicêtre
        • Contact:
        • Principal Investigator:
          • Franck Carbonnel, MD, PhD
      • Paris, France, 75012
        • Not yet recruiting
        • Hôpital Saint Antoine
        • Principal Investigator:
          • Laurent Beaugerie, MD, PhD
        • Contact:
          • Laurent Beaugerie, MD, PhD
      • Paris, France, 75014
        • Recruiting
        • Hopital Cochin
        • Contact:
        • Principal Investigator:
          • Georgia MALAMUT, MD, PhD
        • Principal Investigator:
          • Stanislas CHAUSSADE, MD, PhD
        • Sub-Investigator:
          • Vered ABITBOL, MD, PhD
      • Paris, France, 75010
        • Not yet recruiting
        • Hôpital Saint Louis
        • Principal Investigator:
          • Matthieu Allez, MD, PhD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.

Description

Inclusion Criteria:

  • 18 years or over
  • affiliated to social insurance
  • signed informed consent

Exclusion Criteria:

  • pregnancy
  • under guardianship
  • not able to sign informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Active coeliac patients
Patients with active coeliac disease
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Treated coeliac patients
Patients with coeliac disease on gluten free diet
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Sprue type I
Patients with refractory coeliac disease of type I
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Sprue type II
Patients with refractory coeliac disease of type II
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Intestinal Lymphoproliferations
Patients with intestinal lymphoproliferations
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Non coeliac enteropathies
Patients with non coeliac immune-mediated enteropathy
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Patients without neoplastic or inflammatory intestinal disease
Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intestinal Lymphocytes count
Time Frame: Baseline
Lymphocytes isolation
Baseline
DNA sequencing
Time Frame: Baseline
Targeted Next Generation sequencing
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Georgia MALAMUT, MD, PhD, APHP, Université de Paris (Université Paris Descartes)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 27, 2020

Primary Completion (Anticipated)

February 27, 2028

Study Completion (Anticipated)

February 27, 2028

Study Registration Dates

First Submitted

January 20, 2020

First Submitted That Met QC Criteria

February 20, 2020

First Posted (Actual)

February 21, 2020

Study Record Updates

Last Update Posted (Actual)

July 29, 2020

Last Update Submitted That Met QC Criteria

July 28, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammatory Bowel Diseases

Clinical Trials on Blood sample collection; gastrointestinal biopsy

3
Subscribe